Tumor necrosis factor, interleukin 11, and leukemia inhibitory factor produced by langerhans cells in langerhans cell histiocytosis

Journal of Pediatric Hematology/Oncology

Volumn 26, Issue 11, 2004, Pages 706-711

  By, Ulrika Andersson ^a   Tani, Edneia ^a   Andersson, Ulf ^a   Henter, Jan Inge ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Interleukin 11; Langerhans cell histiocytosis; Leukemia inhibitory factor; Pathogenesis; Tumor necrosis factor

Indexed keywords

CD1 ANTIGEN; INTERLEUKIN 11; LEUKEMIA INHIBITORY FACTOR; TUMOR NECROSIS FACTOR;

ARTICLE; ASPIRATION BIOPSY; CELL DIFFERENTIATION; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CONVALESCENCE; CYTOKINE PRODUCTION; FEMALE; HISTIOCYTE; HISTIOCYTOSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; INFANT; INTRACELLULAR SPACE; LANGERHANS CELL; LANGERHANS CELL HISTIOCYTOSIS; MALE; MOLECULE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; RISK FACTOR; STAINING;

BIOPSY, FINE-NEEDLE; CHILD; CHILD, PRESCHOOL; CYTOKINES; FEMALE; HISTIOCYTOSIS, LANGERHANS-CELL; HUMANS; INFANT; INTERLEUKIN-11; INTERLEUKIN-6; LANGERHANS CELLS; LEUKEMIA INHIBITORY FACTOR; MALE; MICROSCOPY, FLUORESCENCE; OSTEOLYSIS; THROMBOCYTOSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 9644303185     PISSN: 10774114     EISSN: None     Source Type: Journal    
DOI: 10.1097/00043426-200411000-00004     Document Type: Article

References (44)

1. Arceci RJ. The histiocytoses: the fall of the tower of Babel. Eur J Cancer. 1999;35:747-767.
2. Lichtenstein L. Histiocytosis X. Integration of eosinophilic granuloma of bone, "Letterer-Siwe disease" and "Schüller-Christian disease" as related manifestations of a single nosologic entity. AMA Arch Pathol. 1953;56:84-102.
3. Schmitz L, Favara BE. Nosology and pathology of Langerhans cell histiocytosis. Hematol Oncol Clin North Am. 1998;12:221-246.
4. Willis B, Ablin A, Weinberg V, et al. Disease course and late sequelae of Langerhans cell histiocytosis: 25-year experience at the University of California, San Francisco. J Clin Oncol. 1996;14:2073-2082.
5. Gadner H, Heitger A, Grois N, et al. Treatment strategy for disseminated Langerhans cell histiocytosis. DAL HX-83 Study Group. Med Pediatr Oncol. 1994;23:72-80.
6. Gadner H, Grois N, Arico M, et al. A randomized trial of treatment for multisystem Langerhans' cell histiocytosis. J Pediatr. 2001;138:728-734.
7. Willman CL, Busque L, Griffith BB, et al. Langerhans-cell histiocytosis (histiocytosis X): a clonal proliferative disease. N Engl J Med. 1994;331:154-160.
8. Willman CL. Detection of clonal histiocytes in Langerhans cell histiocytosis: biology and clinical significance. Br J Cancer. 1994;70:29-33.
9. Yu RC, Chu C, Buluwela L, et al. Clonal proliferation of Langerhans cells in Langerhans cell histiocytosis. Lancet. 1994;343:767-768.
10. Egeler RM, Willman CL. Is Langerhans cell histiocytosis a myeloid dendritic stem cell disorder related to myelodysplastic disorders? Med Pediatr Oncol. 2000;35:426-427.
11. McClain K, Jin H, Gresik V, et al. Langerhans cell histiocytosis: lack of a viral etiology. Am J Hematol. 1994;47:16-20.
12. Jenson HB, McClain KL, Leach CT, et al. Evaluation of human herpesvirus type 8 infection in childhood Langerhans cell histiocytosis. Am J Hematol. 2000;64:237-241.
13. Ristevski S, Purcell DF, Marshall J, et al. Novel endogenous type D retroviral particles expressed at high levels in a SCID mouse thymic lymphoma. Virology. 1999;73:4662-4669.
14. Savell VH, Sherman T, Scheuermann RH, et al. Bcl-2 expression in Langerhans cell histiocytosis. Pediatr Dev Pathol. 1998;1:210-215.
15. Henter J-I, Karlén J, Calming U, et al. Successful treatment of Langerhans-cell histiocytosis with etanercept. N Engl J Med. 2001;345:1577-1578.
16. Aggarwal BB, Samanta A, Feldmann M. TNFα. In: Oppenheim JJ, Feldmann M, eds. Cytokine Reference. London: Academic Press, 2001:413-434.
17. Keith JC Jr. IL-11. In: Oppenheim JJ, Feldmann M, eds. Cytokine Reference. London: Academic Press, 2001:565-584.
18. Schwertschlag US, Trepicchio WL, Dykstra KH, et al. Hematopoietic, immunomodulatory and epithelial effects of interleukin-11. Leukemia. 1999;13:1307-1315.
19. Girasole G, Passeri G, Jilka RL, et al. Interleukin-11: a new cytokine critical for osteoclast development. J Clin Invest. 1994;93:1516-1524.
20. Manolagas SC. Role of cytokines in bone resorption. Bone. 1995;17:63S-67S.
21. Cornish J, Callon K, King A, et al. The effect of leukemia inhibitory factor on bone in vivo. Endocrinology. 1993;132:1359-1366.
22. Reid LR, Lowe C, Cornish J, et al. Leukemia inhibitory factor: a novel bone-active cytokine. Endocrinology. 1990;126:1416-1420.
23. Calming U, Henter J-I. Elevated ESR and thrombocytosis may be valuable markers of active disease in Langerhans cell histiocytosis. Acta Paediatr. 1998;87:1085-1087.
24. Henter J-I, Söder O, Andersson U. Identification of individual tumour necrosis factor/cachectin-producing cells after lipopolysaccharide induction. Eur J Immunol. 1988;18:983-988.
25. Andersson U, Wang H, Palmblad K, et al. HMG-1 stimulates proinflammatory cytokine synthesis in human monocytes. J Exp Med. 2000;192:565-570.
26. Ulfgren A-K, Andersson U, Engström M, et al. Systemic anti-TNF therapy in rheumatoid arthritis down-regulates synovial TNF synthesis. Arthritis Rheum. 2000;43:2391-2396.
27. Brown RE. Angiotensin-converting enzyme, transforming growth factor beta, and interleukin 11 in the osteolytic lesions of Langerhans cell histiocytosis. Arch Pathol Lab Med. 2000;124:1287-1290.
28. Kannourakis G, Abbas A. The role of cytokines in the pathogenesis of Langerhans cell histiocytosis. Br J Cancer. 1994;70(Suppl XXIII):S37-S40.
29. Egeler RM, Favara BE, van Meurs M, et al. Differential in situ cytokine profiles of Langerhans-like cells and T cells in Langerhans cell histiocytosis: abundant expression of cytokines relevant to disease and treatment. Blood. 1999;94:4195-4201.
30. Foss HD, Herbst H, Araujo I, et al. Monokine expression in Langerhans cell histiocytosis and sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease). J Pathol. 1996;179:60-65.
31. Wu WS, McClain KL. DNA polymorphisms and mutations of the tumor necrosis factor-alpha (TNF-alpha) promotor in Langerhans cell histiocytosis. J Interferon Cytokine Res. 1997;17:631-635.
32. deGraaf JH, Tamminga RY, Dam-Meiring A, et al. The presence of cytokines in Langerhans cell histiocytosis. J Pathol. 1996;180:400-406.
33. Tazi A, Moreau J, Bergeron A, et al. Evidence that Langerhans in adult pulmonary Langerhans cell histiocytosis are mature dendritic cells: importance of the cytokine microenvironment. J Immunol. 1999;163:3511-3515.
34. Sander B, Andersson J, Andersson U. Assessment of cytokines by immunofluorescence and the paraformaldehyde/saponin procedure. Immunol Rev. 1991;119:65-93.
35. Marchini G, Ulfgren AK, Lore K, et al. Erythema toxicum neonatorum: an immunohistochemical analysis. Pediatr Dermatol. 2001;18:177-187.
36. Ulfgren AK, Klareskog L, Lindberg M. An immunohistochemical analysis of cytokine expression in allergic and irritant contact dermatitis. Acta Derm Venereol. 2001;80:167-170.
37. Loré K, Sönnerborg A, Broström C, et al. Accumulation of DC-SIGN+ dendritic cells with reduced CD80 and CD 86 expression in lymphoid tissue during acute HIV-1 infection. AIDS. 2002;16:683-692.
38. Beardsley DS, Nathan DG. Platelet abnormalities in infancy and childhood. In: Nathan DG, Orkin SH, eds. Hematology of Infancy and Childhood. Philadelphia: WB Saunders, 1987:1585-1630.
39. Bhatia S, Nesbit ME, Egeler RM, et al. Epidemiologic study of Langerhans cell histiocytosis in children. J Pediatr. 1997;130:774-784.
40. Calming U, Jacobsson H, Henter J-I. Detection of Langerhans cell histiocytosis lesions with somatostatin analogue scintigraphy: a preliminary report. Med Pediatr Oncol. 2000;35:462-467.
41. Calming U, Bernstrand C, Mosskind M, et al. Brain 18-FDG PET scan in central nervous system Langerhans cell histiocytosis. J Pediatr. 2002;141:435-440.
42. Lipsky PE, van der Heijde DM, St Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med. 2000;343:1594-1602.
43. Sandborn WJ, Hanauer SB. Anti-tumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. Inflamm Bowel Dis. 1999;5:119-133.
44. Lovell DJ, Giannini EH, Reiff A, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl J Med. 2000;342:763-769.